Radiation oncology firm Accuray posted a revenue increase and lower net loss for its first quarter of fiscal 2016 (end-September 30).
For the quarter, the company's revenues were $89.6 million, a 9% increase from $82.4 million in the same period last year. In addition, the company's net loss improved, moving from $21.7 million in the first quarter of 2015 to $9.6 million for the first quarter of 2016.
The company reaffirmed that it expects its fiscal 2016 revenue to be in the range of $395 million to $410 million, a growth of 4% to 8% over fiscal 2015.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
